Ivospemin

Summary

Ivospemin (CHEMBL80386) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including chronic obstructive pulmonary disease and pancreatic ductal adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 7
• Chemistry: 318.5 Da · C16H38N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL80386
Name	Ivospemin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9883501
Molecular formula	C16H38N4O2
Molecular weight	318.5
InChIKey	AFXLPCNTPZQBIC-HOTGVXAUSA-N

SMILES: CCNCC[C@@H](CNCCCCNC[C@H](CCNCC)O)O

IUPAC name: (2S)-4-(ethylamino)-1-[4-[[(2S)-4-(ethylamino)-2-hydroxybutyl]amino]butylamino]butan-2-ol

Also known as: Ivospemin, SBP-101, SUN-101, IVOSPEMIN

Parent form; salt/anhydrous children: CHEMBL5095422

Patent coverage: 15 distinct patent families (45 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
pancreatic ductal adenocarcinoma	2	MONDO:0005184	MONDO:0005184
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
neoplasm	1	MONDO:0005070	EFO:0000616
pancreatic neoplasm	1	MONDO:0021040	EFO:0003860

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	2
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05254171	PHASE2/PHASE3	RECRUITING	Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT02276222	PHASE3	COMPLETED	A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
NCT02347761	PHASE3	COMPLETED	Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
NCT02347774	PHASE3	COMPLETED	Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
NCT02038829	PHASE2	COMPLETED	A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
NCT02657330	PHASE1	COMPLETED	Study of SBP-101 in Pancreatic Cancer
NCT03412799	PHASE1	COMPLETED	Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).